KNS Canada Inc.

Because Life Matters


FibroMeter Bloodmarker

  admin   |     March 10th, 2015   |    

Available now in Canada: FibroMeter Bloodmarker

FibroMeter is a range of blood tests for evaluating the stage of liver fibrosis and cirrhosis. Each FibroMeter test has been specifically designed for the main specific etiologies, using determined sets of markers.

The FibroMeter range covers the 3 main causes of liver diseases

  • Viral hepatitis (Virus)
  • Non-Alcoholic Fatty Liver Disease (NAFLD)
  • Alcoholic Liver Disease (ALD)

FibroMeter Virus

What is the Fibrometer VIRUS?
The Virus FibroMeter® (FibroMeter® V) assesses the stage of liver fibrosis. It has been specifically designed for patients with chronic viral infection, as well as for patients with coinfection.

 

 

FibroMeter NAFLD

What is a FibroMeter NAFLD?
A FibroMeter® NAFLD evaluates the state of liver fibrosis in patients affected by metabolic steatopathy.

 

FibroMeter ALD

What is a FibroMeter ALCOHOL?
A FibroMeter® Alcohol evaluates the stage of liver fibrosis in patients affected by alcoholic liver disease.

 

FibroMeter VCTE

What is FibroMeter VCTE?
It assesses the stage of liver fibrosis in patients with chronic viral hepatitis (B, C) with or without HIV coinfection, and patients with metabolic steatosis.

 

How to use FibroMeter

4 steps protocol

 

Watch Echosens’ Blood Markers Video.
For more information, visit fibrometer.com/en/using-a-fibrometer.html

 

FibroMeter Studies

1) Improved fibrosis staging by elastometry and blood test in chronic hepatitis C

2) The combination of a blood test and FibroScan improves the non-invasive diagnosis of liver fibrosis

3) Comparison of Eight Diagnostic Algorithms for Liver Fibrosis in Hepatitis C: New Algorithms Are More Precise and Entirely Noninvasive

4) A New Combination of Blood Test and FibroScan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C

5) Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease

6) AASLD: “When and in whom to initiate HCV Therapy”